GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
GUIDED THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.16−0.03 (-15.79%)
Close on Oct 19, 2026
- Market cap
- $15.45M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
74.4%−65.8 pts over 5 years
Operating margin
-309.3%+722.1 pts over 5 years
Net margin
-416.7%−143.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10857.1% | +289.3% | +49.7% | +33.7% | |
| Gross profit | +28450.0% | – | +31.9% | +35.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 53.5% | 2.0% | 58.7% | |
| Return on assets | -198.2% | -22.1% | -236.6% | |
| Current ratio | 0.11 | 0.10 | 0.09 | |
| Debt to equity | – | -0.00 | -0.00 | |
| Net debt to EBITDA | – | 0.12× | – | |
| Interest coverage | -2.0× | -1.0× | -3.8× | |
| Inventory turnover | -0.1× | -0.1× | 0.4× | |
| Capex to revenue | – | 1.0% | 0.3% | |
| Diluted shares | 0M | 0M | 78M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Guided Therapeutics generated $7.00M from operations and spent $47.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$7.00M
Used
$47.00K
Capital expenditure$47.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-416.7%
×Asset turnover0.57×
×Equity multiplier-0.25×
=Return on equity, FY202558.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -416.7% | 0.57× | -0.25× | 58.7% |
| FY2024 | -34528.6% | 0.00× | -0.35× | 55.6% |
| FY2023 | -3560.2% | 0.04× | -0.75× | 104.3% |
| FY2022 | -33392.3% | 0.00× | -0.65× | 104.3% |
| FY2021 | -2555.6% | 0.05× | -0.21× | 25.4% |
| FY2020 | -273.5% | 0.08× | -0.09× | 2.0% |
| FY2019 | -5336.1% | 0.05× | -0.04× | 11.7% |
| FY2018 | 1782.5% | 0.18× | -0.02× | -5.8% |
| FY2017 | -4383.6% | 0.26× | -0.07× | 74.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$3.20M
- Cash generatingOperating cash flow above zero-$1.07M
- Return on assets improvedROA up on the prior year-144.8% → -231.9%
- Earnings backed by cashOperating cash flow above net income-$1.07M vs -$3.20M
- Less leverageLong-term debt to assets fell3.4% → 1.7%
- Better liquidityCurrent ratio rose0.19 → 0.09
- No dilutionShare count did not rise57M → 78M
- Gross margin improvedGross margin up on the prior year28.57% → 74.45%
- More efficientAsset turnover rose0.00 → 0.56